Rafutrombopag (tautomerism)
Product Specifications
Product Name Alternative
Hetrombopag (tautomerism); SHR-8735 (tautomerism)
UNSPSC Description
Rafutrombopag (tautomerism) is a potent thrombopoietin receptor agonist. Rafutrombopag (tautomerism) is efficacious and well tolerated with a manageable safety profile. Rafutrombopag (tautomerism) has the potential for the research of immune thrombocytopenia[1].
Target Antigen
Thrombopoietin Receptor
Type
Reference compound
Related Pathways
Immunology/Inflammation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/hetrombopag.html
Purity
98.16
Solubility
DMF : 6.25 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
O=C(C1=CC=C(C2=C(O)C(/N=N/C3C(N(C4=CC=C5C(CCCC5)=C4)N=C3C)=O)=CC=C2)O1)O
Molecular Weight
458.47
References & Citations
[1]Mei H, et al. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol. 2021;14(1):37.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-122620/Rafutrombopag-tautomerism-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-122620/Rafutrombopag-tautomerism-SDS-MedChemExpress.pdf
Clinical Information
Phase 4
CAS Number
2114365-78-3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
